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Cell therapy using tolerogenic dendritic cells in
transplantation
Aurélie Moreau, Emilie Varey, Laurence Bouchet-Delbos and Maria-Cristina Cuturi*
Abstract
Organ transplantation is the main alternative to the loss of vital organ function from various diseases. However, to
avoid graft rejection, transplant patients are treated with immunosuppressive drugs that have adverse side effects.
A new emerging approach to reduce the administration of immunosuppressive drugs is to co-treat patients with
cell therapy using regulatory cells. In our laboratory, as part of a European project, we plan to test the safety of
tolerogenic dendritic cell (TolDC) therapy in kidney transplant patients. In this mini-review, we provide a brief
summary of the major protocols used to derive human TolDC, and then focus on the granulocyte
macrophage-TolDC generated by our own team. Proof of safety of TolDC therapy in the clinic has already been
demonstrated in patients with diabetes. However, in transplantation, DC therapy will be associated with the
administration of immunosuppressive drugs, and interactions between drugs and DC are possible. Finally, we will
discuss the issue of DC origin, as we believe that administration of autologous TolDC is more appropriate, as
demonstrated by our experiments in animal models.
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Introduction
Dendritic cells (DC) are potent antigen-presenting cells
with dual functions; they can be either immunogenic or
tolerogenic in nature. Several protocols of human DC
generation have been described and both types of DC
have clinical applications. Immunogenic DC are used in
patients with cancer to reduce tumor development [1].
Tolerogenic DC (TolDC) therapy appears to be a prom-
ising strategy for the treatment of autoimmune diseases
and transplantation. In this mini-review, we will focus on
human TolDC and their potential clinical application.
Tolerogenic dendritic cells in humans
In the literature, several protocols have been described
for the generation of human TolDC. In these studies,
TolDC have been derived from monocytes (MoDC)
using the cytokines granulocyte macrophage colony-
stimulating factor (GM-CSF) and IL-4. However, as
described for tolerogenic bone marrow-derived DC
(BMDC) in animal models, different drugs or cytokines
could be added to GM-CSF/IL-4 culture to manipulate
human DC in vitro, to obtain TolDC with specific fea-
tures [2]. Among those methods, TolDC can be gener-
ated with vitaminD3 (VitD3). VitD3-treated DC have the
properties of tolerogenic DC; the cells are maturation-
resistant, produce IL-10 after stimulation and induce a
low proliferation of allogeneic T cells [3-5]. More re-
cently, Raïch-Regué et al. showed that VitD3-DC gener-
ated from the monocytes of healthy volunteers or
patients with relapsing remitting multiple sclerosis have
similar properties; a semi-mature phenotype, an anti-
inflammatory profile and a low capacity to induce allo-
geneic T cell proliferation [6]. Furthermore, these cells
seem to show potential for clinical application since
hyporesponsiveness of myelin-reactive T cells from
patients with relapsing remitting multiple sclerosis was
observed when these T cells were cultured with autolo-
gous TolDC loaded with myelin peptides [6]. In parallel,
several studies have investigated the generation of
VitD3-TolDC together with dexamethasone (Dex) in
order to increase their tolerogenic potential [7]. Prior to
the clinical application of these dexamethasone/VitD3
TolDC in rheumatoid arthritis, Harry and colleagues
compared the generation of TolDC from healthy volun-
teers with those from patients with rheumatoid arthritis;
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a similar phenotype and function was observed between
the two groups [8]. In order to favor their migration to
the draining lymph nodes and their antigen presentation
to T cells, VitD3-DC or Dex/VitD3-DC can be matured
in vitro with lipopolysaccharide (LPS). Such cells are
described as alternatively activated DC [9,10] and induce
memory T cell hyporesponsiveness and naive T cell pro-
liferation associated with low IFN-γ and high IL-10 pro-
duction [9]. Other maturation stimuli such as a cytokine
cocktail or monophosphoryl lipid A have also been ana-
lyzed [11].
By contrast to Dex-DC and VitD3-DC, rapamycin-
treated DC (Rapa-DC) express CD83 and CD86 markers
and produce low amounts of IL-10 and high levels of
IL-12p40/p70, characteristics of a mature DC phenotype
[12]. However, Rapa-DC induce low-level proliferation
of allogeneic T cells, similar to Dex-DC and VitD3-DC
[13]. Furthermore, Rapa-DC secrete high levels of IL-12
after LPS stimulation, thereby promoting the induction
of Treg Foxp3+ cells in mice [14]a.
Another important molecule used to generate tolero-
genic DC is IL-10. Two protocols have been used and
lead to the differentiation of different types of TolDC
depending on whether IL-10 is present from the initi-
ation of culture or added at the end. In fact, DC gener-
ated with IL-10 added at the end of culture have an
immature phenotype and display resistance to matur-
ation stimuli [15,16]. These DC induce a state of anergy
in CD4+ T cells [16] and CD8+ T cells [17] in an
antigen-specific manner [18]. More recently, DC derived
from macaque monocytes in the presence of VitD3 and
IL-10 were described as having tolerogenic properties,
including resistance to maturation and low-level induc-
tion of T cell proliferation [19]. The authors demon-
strated the safe intravenous injection of these DC to
major histocompatibility complex (MHC)-mismatched
recipient macaques treated with antihistamine drug and
CTLA4Ig (Cytotoxic T lymphocyte Antigen-4 Ig). A
transient increase in donor antigen-specific T cell prolif-
eration was detected in these animals without any in-
crease in anti-donor antibodies [19]. Another protocol
to generate TolDC with IL-10 consists of culturing
monocytes with IL-10 (in addition to GM-CSF and IL-4)
from the initiation of culture. In this case, TolDC (called
DC10) express CD83, CD80 and CD86, similar to acti-
vated/mature cells, but also Ig-like transcript (ILT)2,
ILT3, ILT4 and human leukocyte antigen G, similar to
Tol-DC. Furthermore, DC10 secrete high levels of IL-10
and induce hyporesponsiveness in allogeneic T cells [20].
A key characteristic of DC generated with IL-10 is their
ability to induce the differentiation of Tr1 regulatory T
cells [20,21]b. Unfortunately, another property of IL-10-
producing DC is a decreased trafficking of these cells to
the lymph nodes. The chemokine CCR7 participates in
the migration of DC to the lymph nodes, and generating
mouse DC with IL-10 down-regulates their expression of
CCR7 and impairs their in vivo homing to lymph nodes
[22]. In a model of mouse cardiac allotransplantation,
Garrod et al. showed that injection of DC co-expressing
IL-10 and CCR7 induced a significant prolongation of
graft survival. However, DC expressing either IL-10 only
or CCR7 only had no effect [23].
Alternative protocols to generate tolerogenic antigen-
presenting cells have been described by other teams,
with the resulting cells being referred to as myeloid-
derived suppressor cells [24]c, mesenchymal stem cells
[25,26]d or regulatory macrophages [27]e. Clinical trials
in transplantation using mesenchymal stem cells and
regulatory macrophages have already been performed.
From the studies described in this section, some
TolDC were generated using a clinical grade protocol
prior to an application in the clinic [6,8,11,13]. In our
center, we chose to generate human TolDC using a sim-
ple protocol in which monocytes are cultured with low-
dose GM-CSF without any additional cytokines or drugs.
This protocol is in accordance with our work performed
in mice [28] and is compatible with a clinical approach.
Generation of human granulocyte macrophage
tolerogenic dendritic cells
Over the last few years, we have generated and charac-
terized tolerogenic BMDC in rats, mice and non-human
primates. In these different models, injection of tolero-
genic BMDC leads to a reduced immune response
in vivo or an induction of tolerance in transplant models
[29-31]. Based on this expertise in TolDC generation in
animals, we decided to derive TolDC in humans from
monocytes in the presence of GM-CSF only. Indeed, the
conventional cytokines used to derive dendritic cells
from precursors are GM-CSF and IL-4. However, a study
performed in mice in 2000 showed that DC generated
with a low dose of GM-CSF in the absence of IL-4 have
the properties of immature tolerogenic DC. These cells
have a high capacity of antigen capture and presentation
and induce a low proliferation of allogeneic T cells. Fur-
thermore, they are maturation-resistant and lead to an
increase of graft survival after in vivo injection [32]. In
parallel, more recently, human MoDC generated in the
presence of GM-CSF and without IL-4 were described to
have tolerogenic properties in vitro [33]. Human GM-
TolDC are derived from monocytes (0.5 million/mL)
cultured with a low dose of GM-CSF (100 U/ml) for
6 days. Different doses of GM-CSF were tested and the
best tolerogenic phenotype was obtained in the presence
of a low dose. In our protocol, medium and cytokines do
not have to be renewed as no difference in the pheno-
type or function of the cells was observed with or with-
out medium and/or cytokines replacement. On day 6,
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cells are harvested and characterized on their phenotype
and their function.
To set up this protocol, we tested methods of mono-
cyte selection. The most common method to obtain
monocytes is to positively select CD14-positive cells
using microbeads. Another possibility is to enrich mono-
cytes from peripheral blood by elutriation. This purifica-
tion technique is based on the separation of cells
according to their size and density [34]. The latter tech-
nique, which has been adapted to Good Manufacturing
Practice facilities, is much cheaper and isolates less
manipulated monocytes. We derived TolDC in AIMV
medium (Gibco Life Technologies) and GM-CSF (Cell-
Genix) using these two techniques from the same donor.
Analysis of the phenotype, function and maturation re-
sistance of the cells generated from both monocyte isola-
tion protocols gave similar results. Thus, all subsequent
experiments were performed with elutriated monocytes.
We next tested different clinical-grade culture media.
We compared GM-TolDC cultured with GM-CSF alone
(100 U/mL) in Roswell Park Memorial Institute (RPMI)/
human albumin medium and in AIMV medium for six
days. In the literature, CellGroDC or X-VIVO 15 me-
diums have also been used to derive human TolDC in
clinical grade conditions [8,13]. Control non-tolerogenic
DC were generated in parallel in the presence of GM-
CSF (100 U/mL) and IL-4 (200 U/mL) in both types of
media. After 6 days of culture, the DC were all non-
adherent in RPMI/albumin medium whereas half of the
cells were adherent in AIMV medium. Analysis of the
phenotype and function of the cells revealed major differ-
ences as the DC generated with RPMI/albumin did not
have tolerogenic properties. As shown in Figure 1A, DC
cultured with RPMI/albumin induced a strong prolifera-
tion of allogeneic T cells, similar to that observed when
T cells were cultured with control DC (either in RPMI/al-
bumin or in AIMV media). By contrast, GM-TolDC in-
duce a very low stimulation of allogeneic T cells, a
feature that we described previously in rat and macaque
tolerogenic BMDC [29,30]. Furthermore, a higher ex-
pression of CD80 was detected at day 6 in RPMI/albu-
min-GM-DC compared with the AIMV-GM-TolDC.
This difference in phenotype was much greater after mat-
uration with LPS/IFNγ, as RPMI/albumin-GM-DC highly
over-expressed CD80, CD86 and CD83 (Figure 1B).
In summary, GM-TolDC were more than 90% MHC-
IIlow CD80low CD86low CD40low with less than 2% con-
tamination with T cells, B cells or natural killer cells.
This immature phenotype of human TolDC is in accord-
ance with the findings of our previous studies in rats,
mice and non-human primates [28-30]. Furthermore, as
we showed previously in rats [35], human GM-TolDC
also expressed the tolerogenic marker Epstein-Barr virus
induced gene 3 protein. As regards to their function,
GM-TolDC induced a weak stimulation of allogeneic
T cells compared with control DC. We also found these
cells to be semi-resistant to maturation induced by LPS/
IFNγ (as shown in Figure 1). In terms of cytokine re-
lease, GM-TolDC produced IL-10 but no IL-12 when
stimulated with LPS/IFNγ. Like their phenotype, the
in vitro function (that is, T cell proliferation induction,
maturation-resistance and cytokine production) of
human GM-TolDC was similar to that of tolerogenic
BMDC described in animal models [28-30]. The similar-
ities between the in vitro features of animal TolDC,
whose efficacy has been proven in vivo, with those
obtained in humans, is encouraging for their potential
use in the clinic.
Clinical application of tolerogenic dendritic cells
Whereas clinical trials using immunogenic DC to treat
cancer have been developed over the last 15 years [1,36],
TolDC therapy is only just emerging in the clinical
arena. This was initiated by the pioneer study published
in 2001 demonstrating the safety of injecting autologous
immature DC into healthy volunteers [37]. Injections of
these DC by the subcutaneous route were well-tolerated
without signs of toxicity or development of autoimmun-
ity. Inhibition of antigen-specific effector T cell function
and induction of antigen-specific CD8 Tregs in vivo
were detected in DC-treated volunteers [37,38]. More
recently, the first phase I clinical trial using TolDC and
including 10 patients was reported in type 1 diabetes
[39]. Control DC generated in the presence of GM-CSF
and IL-4 were injected into three patients while seven
patients received immunosuppressive DC generated in
the presence of GM-CSF, IL-4 and antisense oligonu-
cleotides targeting CD40, CD80 and C86 transcripts. In
this trial, intra-dermal injections of both control and im-
munosuppressive autologous TolDC were well-tolerated
and safe [39]. Furthermore, two clinical trials in rheuma-
toid arthritis are on-going, one by Thomas’s group in
Australia (University of Queensland) and the other one
by Hilkens’s and Isaacs’s group in the UK (University of
Newcastle). These different studies highlight the emer-
gence of tolerogenic DC therapy as a new approach to
treat autoimmune diseases.
As part of a European project, we plan to test the
safety of autologous monocyte-derived TolDC in
patients who have had a kidney transplant. To avoid
graft rejection, transplant patients receive life-long im-
munosuppressive drugs (IS). That means that in this
clinical trial, TolDC will be injected into patients receiv-
ing three IS commonly used in transplantation: tacroli-
mus, mycophenolate mofetil (MMF) and prednisolone.
However, as summarized in Table 1, several studies per-
formed in mice and humans have shown that generation
of DC in the presence of these IS modifies the DC
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phenotype and function. In particular, generation of
mouse BMDC with tacrolimus reduces the ability of DC
to process and/or present antigens [40,41]. All the drug-
treated DC have been shown to induce hypoproliferation
of allogeneic T cells. Interestingly, a study published in
2005 showed that neither migration nor survival of
injected BMDC were affected by tacrolimus-treatment
of recipient rats [42]. Furthermore, co-treatment with
donor DC and tacrolimus increased the hyporesponsive-
ness of recipient T cells. In a model of heart allotrans-
plantation, donor DC alone did not delay rejection while
tacrolimus or tacrolimus + donor DC induced a pro-
longation of graft survival [42]. This work was per-
formed using donor-derived mature BMDC. Prior to the
clinical trial, we will test the absence of toxicity of our
TolDC in IS-treated animals in a mouse skin graft
model. In parallel, graft survival will be monitored in
animals treated with IS without TolDC therapy. So far,
we have noted that injection of MMF induces a pro-
longation of graft survival and injection of TolDC does
not impair this effect. In fact, a slight increase in graft
survival was actually detected (Segovia et al., manuscript
in preparation). Similar experiments using the two other
IS or the combination of both IS associated or not with
DC therapy are on-going. These studies should identify
any potential side effects of DC therapy on the IS treat-
ment used in the clinic.
Others parameters related to DC injections should be
considered before doing a clinical trial, such as the time of
cell product injection, the numbers of DC injected, and also
the number of injections as well as the route of administra-
tion. Regarding this last parameter, experiments performed
in mice have shown that intravenous injection of Dex/LPS-
treated BMDC prolongs cardiac transplant survival whereas
subcutaneous injection of the same Dex/LPS-treated
BMDC does not increase graft survival [58]. Our prelimin-
ary experiments in macaques show that intradermal injec-
tion of autologous TolDC prime an immune response
while intravenous injection does not (unpublished results).
A study also performed in monkeys confirmed the fact that
intravenous injection of TolDC is well-tolerated [19].
The potential of autologous tolerogenic dendritic cells in
transplantation
The clinical trials described in the previous section of
this review either have already been performed or are
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Figure 1 Influence of culture medium on human dendritic cell differentiation in vitro. Four populations of DC were generated in two
different culture media, either RPMI/albumin or AIMV and with two different cytokine conditions, either low-dose GM-CSF (GM-DC) or GM-CSF
and IL-4 (Control DC) for 6 days. (A) The four DC populations were cultured with allogeneic T cells at different ratios for 6 days. A representative
experiment is shown on the left-hand panel. On the right, the results of the ratio of one DC to four Tcells are expressed as the mean T cell
proliferation + standard error of the mean for three different donors (*** P< 0.001, paired T tests). (B) The four populations were un-stimulated
(grey solid histogram) or stimulated with 200 ng/mL LPS and 50 ng/mL IFN-γ (black line) for 48 hours. Cell surface expression of CD80, CD83 and
CD86 was analyzed after 48 hours of culture by flow cytometry. Data shown are representative of two experiments performed..
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on-going in autoimmune diseases. In transplantation,
another parameter has to be taken into consideration;
this is the question of whether TolDC should be derived
from the donor or from the recipient. Most of the stud-
ies described in rodents have been performed using
donor TolDC or recipient TolDC loaded with donor
peptides and administrated one week or more before
transplantation [2]. In this last part, we discuss the rele-
vance of using autologous TolDC from a safety and effi-
cacy point of view.
Firstly and very importantly, the risk of donor
sensitization due to the presence of a slight contaminant
cell product or the destruction of the injected cells by
non-self recognition cannot be excluded using donor
TolDC therapy [59]; we hypothesize that this risk is
minimized using autologous TolDC. Furthermore, to be
efficient, donor TolDC (or donor pulsed recipient
TolDC) need to be sufficiently activated using LPS or
other cytokine cocktails in order to migrate to lymphoid
organs and present the antigen to T cells [9-11]. To
avoid activation-induced maturation, TolDC are also
modified using Dex, VitD3 or IL-10 as described in the
first section of this review. By contrast, in accordance
with our previous work in rodents [30], autologous
Table 1 Effects of tacrolimus, mycophenolate mofetil and prednisolone in tolerogenic dendritic cells generated in vitro
Drugs Models Effects of the drugs on DC and therapeutic effects of the modified DC References
Tacrolimus Mouse BMDC +/−
Tacrolimus
- Reduction in MHC Class I and Class II-restricted presentation of antigen
(role of tacrolimus on Ag processing or presentation)
[40,41,43,44]
- Reduction in pro-inflammatory cytokine (IL-6 and IL-12) secretion and
expression of CD40 and CD86 by BMDC after maturation
- Tacrolimus-treated BMDC induce a low proliferation of allogeneic T cells
- Low CD69 expression and IFN-γ, IL-2 and IL-4 secretion by T cells
stimulated with tacrolimus-treated BMDC
Human MoDC +/−
Tacrolimus
- Low expression of CXCL10 [45-50]
- Reduction in pro-inflammatory cytokine (TNFα and IL-12)
secretion by BMDC after maturation
- Decrease in CD83 and CD86 expression after LPS maturation in the
presence of high levels of tacrolimus only
- Tacrolimus-treated MoDC induce a low level of allogeneic T cell
proliferation, in favor of Th2 cells
- Low CD69 expression and IFN-γ, IL-2 and IL-4 secretion by T cells
stimulated with tacrolimus-treated MoDC (immature or mature)
Mycophenolate
mofetil
Mouse BMDC +/−
MMF
- Decrease in co-stimulatory markers CD80, CD86 and CD40 expression [51,52]
- Decrease in IL-12 production
- MMF-treated BMDC induce a low proliferation of allogeneic T cells
- Decrease in DTH response and increase in allograft survival after
injection of MMF-treated-BMDC
Human MoDC +/−
MMF
- Decrease in co-stimulatory marker expression [53]
- Induction of LPS-maturation resistance (in terms of both
phenotype and cytokine release)
- MMF-treated MoDC induce a low proliferation of allogeneic T cells
- Reduction in endocytic capacity in mature MMF-treated MoDC
(related to mannose receptor expression)
Prednisolone Mouse BMDC +/−
prednisolone
- IL-10/methylprednisolone-treated BMDC increase survival of skin allografts [54]
Human MoDC +/−
prednisolone
- Increase in endocytic capacity [55-57]
- Induction of LPS maturation resistance (absence of
CD80/CD86/CD83 up-regulation)
- Increase in anti-inflammatory cytokines (IL-10 and TGF-β) and decrease in
pro-inflammatory cytokines (IL-6, IL-12, IL-23 and TNFα)
- Prednisolone-treated MoDC induce a low-level proliferation of allogeneic T cells
(which acquire suppressive functions)
BMDC: bone marrow-derived dendritic cells; CD: cluster of differentiation; CXCL10: chemokine (C-X-C motif) ligand 10; IFN-γ: interferon gamma; IL: interleukin;
LPS: lipopolysaccharide; MHC: major histocompatibility complex; MMF: mycophenolate mofetil; MoDC: monocyte-derived dendritic cells; TNF α: tumor necrosis
factor alpha.
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TolDC do not require activation or pulsing to be effi-
cient, leading to a reduced risk of cell maturation. In ac-
cordance with this hypothesis, the first clinical trial
using human TolDC performed with MoDC generated
with GM-CSF and IL-4 showed no toxicity and no ad-
verse effects in the patients injected with these DC [39],
supporting the theory that autologous TolDC do not be-
come immunogenic after injection, correlated with an
absence of maturation of the cells.
Secondly, as regards the efficacy of the cells, some
studies performed recently in mice by Morelli’s group
demonstrated that injected donor DC die quickly after
in vivo injection. Even if administration of donor TolDC
induces tolerance to a transplant, donor TolDC are un-
able to directly regulate an immune response in vivo
[60]. In this context, donor DC mediate their suppres-
sive effects on T cells through endogenous conventional
DC from the recipient mouse [61]. We believe the
mechanisms of action to be different when using autolo-
gous TolDC. Indeed, we detected injected recipient rat
TolDC in the spleen at least two weeks post-injection
[30]. Studies performed in mice and humans have also
shown that DC accumulate in the spleen after intraven-
ous injection [62,63]. Furthermore, our experiments
showed that donor-derived MHC ClassII+ cells from the
graft are present in the spleen of the recipient 3 to 5 days
after transplantation. Stainings performed in the spleens
of these animals suggest that the donor cells interact
with the injected TolDC. Moreover, depletion of graft
passenger leukocytes from the donor organ before trans-
plantation prevents any effect of the autologous TolDC
injection (Segovia et al. submitted manuscript). These
results validate the hypothesis that injected autologous
un-pulsed TolDC are able to migrate to the spleen
where they capture and process the donor antigen from
graft passenger leukocytes (Segovia et al. submitted
manuscript) leading to antigen-specific graft acceptance
[31].
Conclusions
As demonstrated by the clinical trial in patients with
diabetes [39], the use of autologous tolerogenic DC
appears to be a potential safe method that may promote
alloantigen-specific Tcell unresponsiveness and trans-
plant survival. Our experiments performed in animals
suggest that, to be efficient, injected autologous TolDC
have to be in contact with donor antigens and the ad-
ministration of TolDC at the time of the graft is import-
ant. In the clinical trial, patients will be treated with
autologous TolDC at the time of the transplant and will
be additionally treated with low-dose IS (tacrolimus,
prednisolone, MMF). As this will be a phase I trial, we
will test the safety and toxicity of TolDC therapy in
transplantation. However, we cannot exclude the
possibility that IS will have a negative effect on the func-
tion of the injected DC, notably by inhibiting antigen
presentation as already observed when TolDC were gen-
erated with tacrolimus. An alternative could be to
change the drugs used or to wait until a decrease in the
immunosuppressive treatment is possible before inject-
ing the TolDC.
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